SIGA Technologies, Inc. (SIGA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.43 |
| Open | 5.45 |
| Bid | 5.33 x 1300 |
| Ask | 5.65 x 900 |
| Day's Range | 5.41 - 5.63 |
| 52 Week Range | 4.22 - 8.79 |
| Volume | |
| Avg. Volume | 443,574 |
| Market Cap | 398.824M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.08 |
| Earnings Date | Feb 29, 2024 - Mar 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 15, 2023 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SIGA
Related Research
- SIGA Technologies Inc.VNDA: Rating decreased to a SELLVANDA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $5.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat3 months agoArgus Research
Simply Wall St.Investors in SIGA Technologies (NASDAQ:SIGA) have unfortunately lost 44% over the last year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
GlobeNewswireSIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million for Oral TPOXX® (Tecovirimat) - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-s
- GlobeNewswire
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial Officer. A live webcast of the
